ETFs with GENT as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.65%||iShares MSCI Malaysia Index Fund (EWM)||+0.07 (0.44%)|
|3.89%||EGShares Consumer Services GEMS Exchange Traded Fund (VGEM)||+3.54 (18.89%)|
|1.98%||iShares MSCI Emerging Markets Consumer Discrectionary Sector I (EMDI)||+1.44 (2.77%)|
|1.33%||EGShares Emerging Markets CORE ETF (EMCR)||-0.19 (-0.91%)|
|0.52%||PowerShares S&P Emerging Markets Low Volatility Portfolio (EELV)||-0.25 (-0.90%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We started as a group of pharmaceutical businesses founded in Italy in 1944 and have been involved in the research and development of drugs derived from DNA and DNA molecules since the 1970s. In 1993, we were formed by F3F S.p.A. (formerly known as FinSirton S.p.A.) as Pharma Research S.r.L., an Italian private limited company, for the purpose of pursuing research and development activities of prospective pharmaceutical specialty products. In July 2001 we changed our name to Gentium S.p.A.. F3F S.p.A. is one of our largest shareholders owning approximately 17% of our outstanding ordinary shares at December 31, 2012, and may be deemed to be controlled by the Dr. Laura Ferro, our former Chief Executive Officer and President and currently one of our directors, and her family. Under our current bylaws, our company’s term of existence will expire on December 31, 2050. We are governed by the Italian Civil Code. ... More ...